Recent

% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • declaes declaes Sep 22, 2013 3:34 PM Flag

    Aranesp... 1 out of 10

    Information specific to: Aranesp 100micrograms/0.5ml solution for injection pre-filled syringes when used in treating anaemia in people with kidney problems.

    A medicine is only made available to the public if the clinical trials have shown that the benefits of taking the medicine outweigh the risks.
    Once a medicine has been licensed, information on the medicine's effects, both intended and unintended, is continuously recorded and updated.
    Some side-effects may be serious while others may only be a mild inconvenience.
    Everyone's reaction to a medicine is different. It is difficult to predict which side-effects you will have from taking a particular medicine, or whether you will have any side-effects at all. The important thing is to tell your prescriber or pharmacist if you are having problems with your medicine.
    Very common: More than 1 in 10 people who have Aranesp
    hypersensitivity reactions including anaphylactic reactions, angioedema, bronchospasm, skin rash or rashes and urticaria
    raised blood pressure including hypertensive crisis, neurological problems or seizures
    Common: More than 1 in 100 people who have Aranesp
    cerebrovascular problems including stroke
    injection site pain
    redness of the skin
    Uncommon: More than 1 in 1000 people who have Aranesp
    convulsions
    thromboembolism
    The frequency of these side-effects is unknown
    allergic reactions
    production of antibodies to Aranesp

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is known problem for the medical community. FMS caused this issue and both EPO and ARSNEPs are killer drugs.

      That is why Omontys will hit the market sooner than what these bashers think.

      $12-15 easy money.

      GLTA LONGS!

      Sentiment: Strong Buy

 
AFFY
0.105-0.0080(-7.08%)May 27 3:06 PMEDT